MARKET

XRTX

XRTX

Xortx Therapeutics Inc
NASDAQ
0.4801
-0.0162
-3.26%
After Hours: 0.4962 +0.0161 +3.35% 19:30 03/24 EDT
OPEN
0.4850
PREV CLOSE
0.4963
HIGH
0.4900
LOW
0.4301
VOLUME
69.71K
TURNOVER
0
52 WEEK HIGH
2.290
52 WEEK LOW
0.4301
MARKET CAP
8.64M
P/E (TTM)
2.889
1D
5D
1M
3M
1Y
5Y
BRIEF-Xortx Therapeutics Inc- Announce Submission Of A Type D Meeting Request To Us FDA And A Response Setting Date For A Virtual Meeting On May 1, 2023
Reuters · 03/14 11:17
Xortx Announced Type D Meeting With FDA To Be Held May 1, 2023
Benzinga · 03/14 11:07
Xortx stock rises on FDA filing for orphan drug status for kidney disease therapy
Seeking Alpha · 02/01 13:22
BRIEF-XORTX Announces Submission Of Orphan Drug Designation Request For XRx-008 Program
Reuters · 02/01 12:21
XORTX Announced Submission of Orphan Drug Designation Request for XRx-008 Program to Treat Autosomal Dominant Kidney Disease
Benzinga · 02/01 12:05
BRIEF-XORTX Therapeutics Files For Mixed Shelf Of Up To $50 Mln
Reuters · 01/27 12:01
Why FARO Technologies Shares Are Trading Lower By 24%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Benzinga · 01/20 18:24
Dow Drops 150 Points; Crude Oil Up 1%
Benzinga · 01/19 19:54
More
About XRTX
XORTX Therapeutics Inc. is a pharmaceutical company. The Company is focused on identifying, developing and commercializing therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan (rare) disease indications, such as autosomal dominant polycystic kidney disease (ADPKD) and type 2 diabetic nephropathy (T2DN) as well as acute kidney injury (AKI) associated with coronavirus infection. Its three lead product candidates are XRx-008, for the treatment of ADPKD; XRx-101, to treat AKI associated with Coronavirus / COVID-19 infection, AKI and associated health consequences. In addition, XRx-225 is a pre-clinical stage program for type 2 diabetic nephropathy. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company is evaluating xanthine oxidase inhibitor candidates for the XRx-225 program to treat T2DN.

Webull offers kinds of XORTX Therapeutics Inc stock information, including NASDAQ:XRTX real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, XRTX stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading XRTX stock methods without spending real money on the virtual paper trading platform.